Kozak & Associates’s Edwards Lifesciences EW Stock Holding History

Kozak & Associates’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35	Closed	-$2.58K	–	379
2023 Q3	$2.58K	Buy	+35	New	+$2.81K	﹤0.01%	321

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Kozak & Associates's EW Position: Q4 2023 in Review

Kozak & Associates sold out of Edwards Lifesciences (EW) in Q4 2023, closing a stake of 35 shares — an estimated $2.58K sold.

Kozak & Associates first reported a position in EW in Q3 2023 and held it in 1 quarter. The position peaked at $2.58K in Q3 2023. 1,245 funds tracked by Wall St. Rank hold EW as of Q4 2023.

Kozak & Associates reported no remaining Edwards Lifesciences position as of Q4 2023 after selling out during the quarter.
Kozak & Associates sold 35 Edwards Lifesciences shares in Q4 2023, an estimated $2.58K.
Kozak & Associates first reported a position in Edwards Lifesciences in Q3 2023 and held it in 1 quarter.
Kozak & Associates's Edwards Lifesciences position peaked at $2.58K in Q3 2023.
1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2023.

Based on Kozak & Associates's 13F filing for Q4 2023, filed 17 Jan 2024.